Marshall Wace North America L.P. - CYMABAY THERAPEUTICS INC ownership

CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 145 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.76 and the average weighting 0.4%.

Quarter-by-quarter ownership
Marshall Wace North America L.P. ownership history of CYMABAY THERAPEUTICS INC
ValueSharesWeighting
Q1 2020$541,000
+1102.2%
365,866
+4092.8%
0.00%
Q3 2019$45,000
-72.6%
8,726
-61.9%
0.00%
-100.0%
Q2 2019$164,000
-95.0%
22,878
-90.7%
0.00%
-91.7%
Q1 2019$3,262,000
+6173.1%
245,584
+3589.1%
0.01%
+1100.0%
Q4 2018$52,000
-78.5%
6,657
-83.5%
0.00%
-50.0%
Q2 2017$242,00040,4160.00%
Other shareholders
CYMABAY THERAPEUTICS INC shareholders Q1 2019
NameSharesValueWeighting ↓
Foresite Capital Management IV, LLC 1,787,094$26,645,57214.80%
Lynx1 Capital Management LP 994,161$14,822,9419.80%
Octagon Capital Advisors LP 3,073,750$45,829,6137.04%
Saturn V Capital Management LP 1,124,459$16,765,6847.02%
Altium Capital Management LP 800,000$11,928,0006.22%
Affinity Asset Advisors, LLC 1,129,376$16,838,9964.74%
ACUTA CAPITAL PARTNERS, LLC 418,000$6,232,3804.18%
Cormorant Asset Management, LP 3,850,000$57,403,5003.35%
SILVERARC CAPITAL MANAGEMENT, LLC 590,000$8,796,9002.67%
MPM BioImpact LLC 610,770$9,106,5812.43%
View complete list of CYMABAY THERAPEUTICS INC shareholders